These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

213 related articles for article (PubMed ID: 33280619)

  • 1. The benefits of betahistine or vestibular rehabilitation (Tetrax biofeedback) on the quality of life and fall risk in patients with Ménière's disease.
    Liu JL; Liu JG; Chen XB; Liu YH
    J Laryngol Otol; 2020 Dec; 134(12):1073-1076. PubMed ID: 33280619
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vestibular rehabilitation with virtual reality in Ménière's disease.
    Garcia AP; Ganança MM; Cusin FS; Tomaz A; Ganança FF; Caovilla HH
    Braz J Otorhinolaryngol; 2013; 79(3):366-74. PubMed ID: 23743754
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Report from a Consensus Conference on the treatment of Ménière's disease with betahistine: rationale, methodology and results.
    Casani AP; Guidetti G; Schoenhuber R;
    Acta Otorhinolaryngol Ital; 2018 Oct; 38(5):460-467. PubMed ID: 30498275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Hearing function after betahistine therapy in patients with Ménière's disease.
    Seyed Tootoonchi SJ; Ghiasi S; Shadara P; Samani SM; Fouladi DF
    Braz J Otorhinolaryngol; 2016; 82(5):500-6. PubMed ID: 26810620
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Medical management of Ménière's disease: a 10-year case series and review of literature.
    Martín González C; González FM; Trinidad A; Ibáñez A; Pinilla M; Martínez Ruiz-Coello A; Rodríguez Valiente A; López-Cortijo C
    Eur Arch Otorhinolaryngol; 2010 Sep; 267(9):1371-6. PubMed ID: 20454798
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Using betahistine in the treatment of patients with Menière's disease: a meta-analysis with the current randomized-controlled evidence.
    Devantier L; Hougaard D; Händel MN; Liviu-Adelin Guldfred F; Schmidt JH; Djurhuus B; Callesen HE
    Acta Otolaryngol; 2020 Oct; 140(10):845-853. PubMed ID: 32580600
    [No Abstract]   [Full Text] [Related]  

  • 7. Efficacy and safety of betahistine treatment in patients with Meniere's disease: primary results of a long term, multicentre, double blind, randomised, placebo controlled, dose defining trial (BEMED trial).
    Adrion C; Fischer CS; Wagner J; Gürkov R; Mansmann U; Strupp M;
    BMJ; 2016 Jan; 352():h6816. PubMed ID: 26797774
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Betahistine or Cinnarizine for treatment of Meniere's disease.
    Djelilovic-Vranic J; Alajbegovic A; Tiric-Campara M; Volic A; Sarajlic Z; Osmanagic E; Todorovic L; Beslagic O
    Med Arch; 2012; 66(6):396-8. PubMed ID: 23409520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Medical treatment in Ménière's disease: avoiding vestibular neurectomy and facilitating postoperative compensation.
    Colletti V
    Acta Otolaryngol Suppl; 2000; 544():27-33. PubMed ID: 10904798
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient Perceptions of Effectiveness in Treatments for Menière's Disease: a National Survey in Italy.
    Ward B; Wettstein V; Golding J; Corallo G; Nuti D; Trabalzini F; Mandala M
    J Int Adv Otol; 2019 Apr; 15(1):112-117. PubMed ID: 31058600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fixed combination of cinnarizine and dimenhydrinate versus betahistine dimesylate in the treatment of Ménière's disease: a randomized, double-blind, parallel group clinical study.
    Novotný M; Kostrica R
    Int Tinnitus J; 2002; 8(2):115-23. PubMed ID: 14763223
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Meta-analysis of clinical studies with betahistine in Ménière's disease and vestibular vertigo.
    Nauta JJ
    Eur Arch Otorhinolaryngol; 2014 May; 271(5):887-97. PubMed ID: 23778722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [A study of the efficacy and safety of a new modified-release betahistine formulation in the treatment of vestibular vertigo and Meniere's disease].
    Parfenov VA; Zamergrad MV; Kazei DV; Nauta J
    Zh Nevrol Psikhiatr Im S S Korsakova; 2020; 120(12):42-48. PubMed ID: 33459540
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The use of betaserk in patients with cochlear-vestibular disorders].
    Kadymov MI; Poliakova TS; Vladimirova TN
    Vestn Otorinolaringol; 1998; (5):49-50. PubMed ID: 9793432
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Non-drug therapy of vertigo].
    Antonenko LM; Parfenov VA
    Zh Nevrol Psikhiatr Im S S Korsakova; 2018; 118(8):38-42. PubMed ID: 30251976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improving the quality of life in patients with vestibular disorders: the role of medical treatments and physical rehabilitation.
    Mira E
    Int J Clin Pract; 2008 Jan; 62(1):109-14. PubMed ID: 17537195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of betahistine in the treatment of peripheral vertigo.
    Ramos Alcocer R; Ledezma Rodríguez JG; Navas Romero A; Cardenas Nuñez JL; Rodríguez Montoya V; Deschamps JJ; Liviac Ticse JA
    Acta Otolaryngol; 2015; 135(12):1205-11. PubMed ID: 26245698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Betahistine in Ménière's Disease or Syndrome: A Systematic Review.
    Van Esch B; van der Zaag-Loonen H; Bruintjes T; van Benthem PP
    Audiol Neurootol; 2022; 27(1):1-33. PubMed ID: 34233329
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Betahistine in vestibular disorders: current concepts and perspectives].
    Zamergrad MV; Kunelskaya NL; Guseva AL; Amelin AV; Lilenko SV; Samartcev IN; Zaytseva OV; Melnikov OA; Voronov VA; Lyapin AV
    Vestn Otorinolaringol; 2021; 86(2):73-81. PubMed ID: 33929156
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Betahistine for Menière's disease or syndrome.
    James AL; Burton MJ
    Cochrane Database Syst Rev; 2001; 2001(1):CD001873. PubMed ID: 11279734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.